Adherence with brand versus generic bisphosphonates among newly treated osteoporosis patients: a retrospective cohort study in the French claims database - Archive ouverte HAL Accéder directement au contenu
Poster De Conférence Année : 2018

Adherence with brand versus generic bisphosphonates among newly treated osteoporosis patients: a retrospective cohort study in the French claims database

Résumé

Results  During the 2009-2015 period, 3,903 patients initiated an oral BP treatment for primary OP: 1,710 (43.8%) with generic BP and 2,193 (56.2%) with brand BP. Results of switches and implementation rates according to BP group are presented in Table 1.  Univariate analyses were conducted to identify factors associated with good implementation (defined by CMA7 ≥ 0.9). Factors tested were: exposition of interest (BP group) , year of initiation, frequency of BP administration, oral BP molecule, prescriber specialty, age, sex, presence of a major chronic disease, socioeconomic frailty, polypharmacy, history of osteoporotic fracture, Charlson comorbidity index.  Binary logistic regression modelling was then used to predict good implementation, by stepwise addition of exposition of interest and variables associated with good implementation at a probability level of 0.2 or less in bivariate analyses. Results of multivariate analysis are presented in Table 2.
Fichier principal
Vignette du fichier
Poster ESPACOMP 2018 GENEROS.pdf (482.08 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04330955 , version 1 (08-12-2023)

Identifiants

  • HAL Id : hal-04330955 , version 1

Citer

M Viprey, Y Xu, A Rousseau, F Abbas, A Dima, et al.. Adherence with brand versus generic bisphosphonates among newly treated osteoporosis patients: a retrospective cohort study in the French claims database. 22nd ESPACOMP conference, Nov 2018, Dublin, Ireland. ⟨hal-04330955⟩
4 Consultations
2 Téléchargements

Partager

Gmail Facebook X LinkedIn More